This binding induces angiogenesis and makes HCC cells resistant to sorafenib; however, treatment with an ANGPT2 monoclonal antibody significantly reduces the growth of tumors overexpressing MYBL1 and effectively inhibits angiogenesis (43). This evidence concerns the gene MYBL1 and hepatocellular carcinoma.